Headquarters
South San Francisco, California
Company size
30-39
Since
2016

About Us

Enzyme’s mission is to automate and simplify life science regulatory approval and compliance. We reduce your cost of compliance and help bring your cutting-edge technology to market faster.

Our cloud based Quality Management System (QMS) streamlines documentation and integrates with tools you are already using. And our experts guide you through your entire regulatory and compliance lifecycle: from pre-submission, to product design and development, regulatory submission, and post-market compliance.

Enzyme supports all life science companies, with an emphasis on companies making digital health, or software as a medical device (SaMD), products.

Current Jobs

😔 Oops...

No jobs for today, my friend. No worries though!
Come back later and we'll find something for you!

Would you like to work here?

Add this company as an ideal employer to indicate your interest confidentially.

Employee reviews

👎 👍

Work at Enzyme? Share your experiences.

Add Review

Your email address will not be published. Required fields are marked *

Your review should be truthful and reflect your own personal opinion and experience. The review will be rejected if it includes spam, false information, insults/profanity, abusive or threatening language, attacks or any content that violates the rights of others or does not comply with.

Deals and promo codes

There are no special offers here yet. Try to check later.

Twitter feed

DC Circuit Court strikes down FDA's ban of a device for a specific use, ruling that it amounts to regulating the practice of medicine, a power not granted to the Agency.
#FDA #CircuitCourt @RAPSorg @aami_connect
https://www.enzyme.com/blog/circuit-court-sides-with-rotenberg-against-fda

Tues 7/27, FDA hosts webinar to discuss 2 recent publications @EnzymeCorp featured in blogs - the Draft Guidance Remanufacturing of Medical Devices & the discussion paper for Strengthening Cybersecurity Practices w/ Servicing Medical Devices http://shorturl.at/oJLN0

Draft VALID Act expands FDA authority over IVCTs modified by users, and its phase-in could be < 3 years.

#FDA @RAPSorg @aami_connect #IVDD

https://www.enzyme.com/blog/new-valid-act-phase-in-may-be-as-short-as-three-years

WHO raises several key principles to consider in the evolving regulatory landscape of AI medical devices.

@WHO @FDAcdrhIndustry #artificialintelligence #medicaldevice #machinelearning @RAPSorg
https://www.enzyme.com/blog/who-enters-ai-debate-with-report-on-guiding-principles

Remanufacturers be warned - 21 CFR Part 820 is indeed a part of your life. If a party deliberately or inadvertently improves safety or performance - this may be deemed remanufacturing, including cumulative effects of multiple servicings. #medicaldevices https://www.enzyme.com/blog/fda-cites-record-keeping-inspections-in-remanufacturing-draft

FDA's multi-tiered medical device cybersecurity guidance landscape gets more complex as FDA releases new draft guidance on the servicing and remanufacturing of software in/as medical devices. https://www.enzyme.com/blog/fda-developing-cybersecurity-policy-for-serviced-devices

@RAPSorg @aami_connect #FDA #SaMD #cybersecurity #medicaldevice

New draft EC AI legislation is likely to increase regulatory burden for AI products in the EU.

@RAPSorg #artificialintelligence #machinelearning #SaMD @ASQ #cemarking #medicaldevice

https://www.enzyme.com/blog/eu-draft-legislation-for-ai-may-add-regulatory-hurdles

FDA announces new draft guidance for Section 522 studies, shortening timelines and improving transparency.

@FDAcdrhIndustry @RAPSorg #postmarketsurveillance @ASQ

https://www.enzyme.com/blog/fda-tightens-turn-around-times-for-section-522-studies

One of the difficult parts of risk management is that FDA’s provisions are scattered across several guidances. This blog post summarizes some of the provisions. https://www.enzyme.com/blog/fda-iso-and-the-risk-management-quandary #fda #riskmanagement #medicaldevices

FDA updates draft guidance on medical device products demonstrating electromagnetic compatibility (EMC). #fda #medicaldevices https://www.enzyme.com/blog/fda-electromagnetic-compatibility-requirements-growing

The IMDRF has released its five-year strategic plan for regulatory convergence which includes considerations for cybersecurity and AI, and a single premarket review process for medical devices. https://www.enzyme.com/blog/imdrfs-five-year-plan #AI #healthcare #cybersecurity

FDA’s Safer Technologies Program offers a quicker review process for products that significantly improve the patient risk-benefit profile. https://www.enzyme.com/blog/fda-step-program-offers-expedited-review #fda #digitalhealth

The EU’s Medical Device Coordination Group has updated its policy on remote audits during the COVID-19 pandemic. https://www.enzyme.com/blog/remote-audits-gaining-traction-in-the-era-of-covid-19 #COVID19 #DigitalHealth #COVID19

YC Bio founders often ask us when they should start thinking about the FDA. @reshmakhilnani and @seehafer outline basic rules for this complex question. https://blog.ycombinator.com/the-pre-product-startup-and-the-fda/

YC Bio founders often ask us about the FDA and the broader regulatory environment. @reshmakhilnani and @seehafer touch on some of the most important concepts bio founders should think about and distills them down to their essence.
https://blog.ycombinator.com/fda-orientation-for-early-stage-startups/

Load More...

FAQ

Where is Enzyme headquarters?

Enzyme headquarters is located at South San Francisco, California.

When was Enzyme founded?

Enzyme was founded in 2016.

How many employees does Enzyme have?

Enzyme has 30-39 employees.

What is Enzyme's core business?

Enzyme is Computer Software company.

Claim this company page

Claim your company profile

We've built profiles for the fastest growing companies.

Let's verify you work at Enzyme.
We'll use your work email to confirm you're an employee at Enzyme.
Claim Now
Need help with anything? Get in touch

Share this company